O	O	0	12	Amelioration	Amelioration	B-NP	NN	O	0	ROOT	O
O	O	13	15	of	of	B-PP	IN	O	1	NMOD	O
O	O	16	19	rat	rat	B-NP	NN	O	5	NMOD	O
O	O	20	28	cerulein	cerulein	I-NP	NN	O	5	NMOD	O
O	O	29	41	pancreatitis	pancreatitis	I-NP	NN	O	2	PMOD	O
O	O	42	44	by	by	B-PP	IN	O	1	NMOD	O
T1	B-Entity	45	53	guamerin	guamerin	B-NP	NN	B-protein	10	NMOD	B-protein
T1	I-Entity	53	54	-	-	O	HYPH	O	10	NMOD	O
T1	I-Entity	54	61	derived	derive	B-NP	VBN	O	10	NMOD	O
T1	I-Entity	62	69	peptide	peptide	I-NP	NN	O	15	NMOD	O
O	O	69	70	,	,	O	,	O	15	P	O
O	O	71	72	a	a	B-NP	DT	O	15	NMOD	O
O	O	73	78	novel	novel	I-NP	JJ	O	15	NMOD	O
O	O	79	87	elastase	elastase	I-NP	NN	B-protein	15	NMOD	B-protein
O	O	88	97	inhibitor	inhibitor	I-NP	NN	O	6	PMOD	O
O	O	97	98	.	.	O	.	O	1	P	O

O	O	100	109	Increased	Increase	B-NP	VBN	O	2	NMOD	O
O	O	110	118	activity	activity	I-NP	NN	O	6	SUB	O
O	O	119	121	of	of	B-PP	IN	O	2	NMOD	O
O	O	122	129	various	various	B-NP	JJ	O	5	NMOD	O
O	O	130	139	proteases	protease	I-NP	NNS	B-protein	3	PMOD	B-protein
O	O	140	142	is	be	B-VP	VBZ	O	29	VMOD	O
O	O	143	151	observed	observe	I-VP	VBN	O	6	VC	O
O	O	152	154	in	in	B-PP	IN	O	7	VMOD	O
O	O	155	159	both	both	B-NP	CC	O	12	AMOD	O
O	O	160	165	human	human	I-NP	JJ	O	12	AMOD	O
O	O	166	169	and	and	I-NP	CC	O	12	AMOD	O
O	O	170	182	experimental	experimental	I-NP	JJ	O	13	NMOD	O
O	O	183	195	pancreatitis	pancreatitis	I-NP	NN	O	8	PMOD	O
O	O	195	196	;	;	O	:	O	29	P	O
O	O	197	204	however	however	B-ADVP	RB	O	29	VMOD	O
O	O	204	205	,	,	O	,	O	29	P	O
O	O	206	209	the	the	B-NP	DT	O	18	NMOD	O
O	O	210	221	information	information	I-NP	NN	O	29	SUB	O
O	O	222	224	on	on	B-PP	IN	O	18	NMOD	O
O	O	225	228	the	the	B-NP	DT	O	21	NMOD	O
O	O	229	236	effects	effect	I-NP	NNS	O	19	PMOD	O
O	O	237	239	of	of	B-PP	IN	O	21	NMOD	O
O	O	240	248	specific	specific	B-NP	JJ	O	25	NMOD	O
O	O	249	257	protease	protease	I-NP	NN	O	25	NMOD	O
O	O	258	268	inhibitors	inhibitor	I-NP	NNS	O	22	PMOD	O
O	O	269	271	on	on	B-PP	IN	O	21	NMOD	O
O	O	272	275	the	the	B-NP	DT	O	28	NMOD	O
O	O	276	283	disease	disease	I-NP	NN	O	26	PMOD	O
O	O	284	286	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	287	294	limited	limit	B-ADJP	VBN	O	29	PRD	O
O	O	294	295	.	.	O	.	O	29	P	O

O	O	296	298	In	In	B-PP	IN	O	5	VMOD	O
O	O	299	303	this	this	B-NP	DT	O	3	NMOD	O
O	O	304	309	study	study	I-NP	NN	O	1	PMOD	O
O	O	310	312	we	we	B-NP	PRP	O	5	SUB	O
O	O	313	317	show	show	B-VP	VBP	O	0	ROOT	O
O	O	318	322	that	that	B-SBAR	IN	O	5	VMOD	O
O	O	323	324	a	a	B-NP	DT	O	10	NMOD	O
O	O	325	330	novel	novel	I-NP	JJ	O	10	NMOD	O
O	O	331	339	elastase	elastase	I-NP	NN	B-protein	10	NMOD	B-protein
O	O	340	349	inhibitor	inhibitor	I-NP	NN	O	12	NMOD	O
O	O	349	350	,	,	O	,	O	12	P	O
T2	B-Entity	351	359	guamerin	guamerin	B-NP	NN	O	21	SUB	O
T2	I-Entity	359	360	-	-	O	HYPH	O	12	P	O
T2	I-Entity	360	367	derived	derive	B-VP	VBN	O	12	NMOD	O
T2	I-Entity	368	377	synthetic	synthetic	B-NP	JJ	O	16	NMOD	O
T2	I-Entity	378	385	peptide	peptide	I-NP	NN	O	14	VMOD	O
O	O	386	387	(	(	O	(	O	19	DEP	O
T3	B-Entity	387	391	GDSP	GDSP	B-NP	NN	O	19	DEP	O
O	O	391	392	)	)	O	)	O	16	NMOD	O
O	O	392	393	,	,	O	,	O	12	P	O
O	O	394	402	improves	improve	B-VP	VBZ	O	6	SBAR	O
O	O	403	406	the	the	B-NP	DT	O	23	NMOD	O
O	O	407	417	parameters	parameter	I-NP	NNS	O	21	OBJ	O
O	O	418	420	of	of	B-PP	IN	O	23	NMOD	O
T4	B-Entity	421	429	cerulein	cerulein	B-NP	NN	O	29	NMOD	O
O	O	429	430	-	-	B-NP	HYPH	O	29	NMOD	O
O	O	430	437	induced	induce	I-NP	VBN	O	29	NMOD	O
O	O	438	443	acute	acute	I-NP	JJ	O	29	NMOD	O
O	O	444	456	pancreatitis	pancreatitis	I-NP	NN	O	24	PMOD	O
O	O	457	459	in	in	B-PP	IN	O	29	NMOD	O
O	O	460	463	the	the	B-NP	DT	O	32	NMOD	O
O	O	464	467	rat	rat	I-NP	NN	O	30	PMOD	O
O	O	467	468	.	.	O	.	O	5	P	O

O	O	469	472	The	The	B-NP	DT	O	2	NMOD	O
O	O	473	480	effects	effect	I-NP	NNS	O	33	SUB	O
O	O	481	483	of	of	B-PP	IN	O	2	NMOD	O
T5	B-Entity	484	488	GDSP	GDSP	B-NP	NN	O	3	PMOD	O
O	O	489	491	on	on	B-PP	IN	O	2	NMOD	O
O	O	492	502	pancreatic	pancreatic	B-NP	JJ	O	7	NMOD	O
O	O	503	509	weight	weight	I-NP	NN	O	32	NMOD	O
O	O	509	510	,	,	O	,	O	32	P	O
O	O	511	516	serum	serum	B-NP	NN	B-protein	12	NMOD	B-protein
O	O	517	524	amylase	amylase	I-NP	NN	I-protein	12	NMOD	I-protein
O	O	525	528	and	and	I-NP	CC	I-protein	12	NMOD	I-protein
O	O	529	535	lipase	lipase	I-NP	NN	I-protein	32	NMOD	I-protein
O	O	535	536	,	,	O	,	O	32	P	O
O	O	537	548	morphologic	morphologic	B-NP	JJ	O	15	NMOD	O
O	O	549	556	changes	change	I-NP	NNS	O	32	NMOD	O
O	O	557	559	in	in	B-PP	IN	O	15	NMOD	O
O	O	560	563	the	the	B-NP	DT	O	18	NMOD	O
O	O	564	572	pancreas	pancreas	I-NP	NN	O	16	PMOD	O
O	O	572	573	,	,	O	,	O	32	P	O
O	O	574	584	neutrophil	neutrophil	B-NP	NN	O	21	NMOD	O
O	O	585	597	infiltration	infiltration	I-NP	NN	O	32	NMOD	O
O	O	597	598	,	,	O	,	O	32	P	O
O	O	599	602	and	and	O	CC	O	26	NMOD	O
T6	B-Entity	603	610	nuclear	nuclear	B-NP	JJ	B-protein	26	NMOD	B-protein
T6	I-Entity	611	617	factor	factor	I-NP	NN	I-protein	26	NMOD	I-protein
T6	I-Entity	618	620	KB	KB	I-NP	NN	I-protein	32	NMOD	I-protein
O	O	621	622	(	(	O	(	O	31	DEP	O
T7	B-Entity	622	624	NF	NF	B-NP	NN	B-protein	30	NMOD	B-protein
T7	I-Entity	624	625	-	-	B-NP	HYPH	I-protein	30	P	I-protein
T7	I-Entity	625	627	KB	KB	I-NP	NN	I-protein	31	DEP	I-protein
O	O	627	628	)	)	O	)	O	26	NMOD	O
O	O	629	639	activation	activation	B-NP	NN	O	5	PMOD	O
O	O	640	644	were	be	B-VP	VBD	O	0	ROOT	O
O	O	645	653	measured	measure	I-VP	VBN	O	33	VC	O
O	O	654	656	in	in	B-PP	IN	O	34	VMOD	O
O	O	657	661	rats	rat	B-NP	NNS	O	35	PMOD	O
O	O	662	669	infused	infuse	B-VP	VBN	O	36	NMOD	O
O	O	670	674	with	with	B-PP	IN	O	37	VMOD	O
O	O	675	687	supramaximal	supramaximal	B-NP	JJ	O	40	NMOD	O
O	O	688	692	dose	dose	I-NP	NN	O	38	PMOD	O
O	O	693	695	of	of	B-PP	IN	O	40	NMOD	O
O	O	696	704	cerulein	cerulein	B-NP	NN	O	41	PMOD	O
O	O	705	706	(	(	O	(	O	51	DEP	O
O	O	706	707	5	5	B-NP	CD	O	51	DEP	O
O	O	708	709	(	(	O	(	O	51	DEP	O
O	O	709	710	g	g	B-NP	NN	O	50	NMOD	O
O	O	710	711	/	/	B-NP	SYM	O	50	P	O
O	O	711	713	kg	kg	I-NP	NN	O	50	NMOD	O
O	O	713	714	/	/	I-NP	SYM	O	50	P	O
O	O	714	715	h	h	I-NP	NN	O	51	DEP	O
O	O	715	716	)	)	O	)	O	40	NMOD	O
O	O	717	720	for	for	B-PP	IN	O	37	VMOD	O
O	O	721	722	6	6	B-NP	CD	O	54	NMOD	O
O	O	723	724	h	h	I-NP	NN	O	52	PMOD	O
O	O	724	725	.	.	O	.	O	33	P	O

O	O	726	729	The	The	B-NP	DT	O	2	NMOD	O
O	O	730	737	effects	effect	I-NP	NNS	O	5	SUB	O
O	O	738	740	of	of	B-PP	IN	O	2	NMOD	O
T8	B-Entity	741	745	GDSP	GDSP	B-NP	NN	O	3	PMOD	O
O	O	746	750	were	be	B-VP	VBD	O	0	ROOT	O
O	O	751	755	also	also	I-VP	RB	O	5	VMOD	O
O	O	756	764	measured	measure	I-VP	VBN	O	5	VC	O
O	O	765	767	on	on	B-PP	IN	O	7	VMOD	O
O	O	768	778	superoxide	superoxide	B-NP	NN	O	10	NMOD	O
O	O	779	788	formation	formation	I-NP	NN	O	8	PMOD	O
O	O	789	791	by	by	B-PP	IN	O	10	NMOD	O
O	O	792	801	activated	activate	B-NP	VBN	B-cell_type	14	NMOD	B-cell_type
O	O	802	807	human	human	I-NP	JJ	I-cell_type	14	NMOD	I-cell_type
O	O	808	819	neutrophils	neutrophil	I-NP	NNS	I-cell_type	11	PMOD	I-cell_type
O	O	819	820	.	.	O	.	O	5	P	O

O	O	821	824	The	The	B-NP	DT	O	2	NMOD	O
O	O	825	832	effects	effect	I-NP	NNS	O	5	SUB	O
O	O	833	835	of	of	B-PP	IN	O	2	NMOD	O
T9	B-Entity	836	840	GDSP	GDSP	B-NP	NN	O	3	PMOD	O
O	O	841	845	were	be	B-VP	VBD	O	0	ROOT	O
O	O	846	854	compared	compare	I-VP	VBN	O	5	VC	O
O	O	855	859	with	with	B-PP	IN	O	6	VMOD	O
O	O	860	865	those	those	B-NP	DT	O	7	PMOD	O
O	O	866	868	of	of	B-PP	IN	O	8	NMOD	O
O	O	869	876	another	another	B-NP	DT	O	12	NMOD	O
O	O	877	885	elastase	elastase	I-NP	NN	B-protein	12	NMOD	B-protein
O	O	886	895	inhibitor	inhibitor	I-NP	NN	O	14	NMOD	O
O	O	895	896	,	,	O	,	O	14	P	O
O	O	897	908	elastatinal	elastatinal	B-ADJP	JJ	O	9	PMOD	O
O	O	908	909	.	.	O	.	O	5	P	O

T10	B-Entity	910	914	GDSP	GDSP	B-NP	NN	O	3	SUB	O
O	O	915	928	significantly	significantly	B-ADVP	RB	O	3	VMOD	O
O	O	929	938	inhibited	inhibit	B-VP	VBD	O	19	VMOD	O
O	O	939	944	edema	edema	B-NP	NN	O	5	NMOD	O
O	O	945	954	formation	formation	I-NP	NN	O	16	NMOD	O
O	O	954	955	,	,	O	,	O	16	P	O
O	O	956	966	neutrophil	neutrophil	B-NP	NN	O	8	NMOD	O
O	O	967	979	infiltration	infiltration	I-NP	NN	O	16	NMOD	O
O	O	979	980	,	,	O	,	O	16	P	O
O	O	981	987	acinar	acinar	B-NP	JJ	O	12	NMOD	O
O	O	988	992	cell	cell	I-NP	NN	O	12	NMOD	O
O	O	993	999	damage	damage	I-NP	NN	O	16	NMOD	O
O	O	999	1000	,	,	O	,	O	16	P	O
O	O	1001	1004	and	and	O	CC	O	16	NMOD	O
O	O	1005	1011	plasma	plasma	B-NP	NN	B-protein	16	NMOD	B-protein
O	O	1012	1018	lipase	lipase	I-NP	NN	I-protein	3	OBJ	I-protein
O	O	1019	1022	and	and	O	CC	O	19	VMOD	O
O	O	1023	1030	amylase	amylase	B-NP	NN	B-protein	19	SUB	B-protein
O	O	1031	1040	increases	increase	I-NP	NNS	O	0	ROOT	O
O	O	1041	1047	caused	cause	B-VP	VBN	O	19	VMOD	O
O	O	1048	1050	by	by	B-PP	IN	O	20	VMOD	O
O	O	1051	1059	cerulein	cerulein	B-NP	NN	O	21	PMOD	O
O	O	1059	1060	.	.	O	.	O	19	P	O

T11	B-Entity	1061	1065	GDSP	GDSP	B-NP	NN	O	4	SUB	O
O	O	1066	1070	also	also	B-ADVP	RB	O	4	VMOD	O
O	O	1071	1081	completely	completely	B-ADVP	RB	O	4	VMOD	O
O	O	1082	1091	inhibited	inhibit	B-VP	VBD	O	0	ROOT	O
O	O	1092	1102	superoxide	superoxide	B-NP	NN	O	6	NMOD	O
O	O	1103	1112	formation	formation	I-NP	NN	O	4	OBJ	O
O	O	1113	1115	in	in	B-PP	IN	O	6	NMOD	O
O	O	1116	1119	the	the	B-NP	DT	O	10	NMOD	O
O	O	1120	1125	human	human	I-NP	JJ	B-cell_type	10	NMOD	B-cell_type
O	O	1126	1137	neutrophils	neutrophil	I-NP	NNS	I-cell_type	36	NMOD	I-cell_type
O	O	1138	1148	stimulated	stimulate	B-VP	VBN	O	10	NMOD	O
O	O	1149	1151	by	by	B-PP	IN	O	11	VMOD	O
T12	B-Entity	1152	1153	N	N	B-NP	NN	B-protein	15	NMOD	B-protein
T12	I-Entity	1153	1154	-	-	B-NP	HYPH	I-protein	15	P	I-protein
T12	I-Entity	1154	1160	formyl	formyl	I-NP	NN	I-protein	12	PMOD	I-protein
T12	I-Entity	1160	1161	-	-	B-NP	HYPH	O	36	NMOD	O
T12	I-Entity	1161	1171	methionine	methionine	I-NP	NN	O	36	NMOD	O
T12	I-Entity	1171	1172	-	-	B-NP	HYPH	O	36	NMOD	O
T12	I-Entity	1172	1179	leucine	leucine	I-NP	NN	O	36	NMOD	O
T12	I-Entity	1179	1180	-	-	B-NP	HYPH	O	36	NMOD	O
T12	I-Entity	1180	1186	phenyl	phenyl	I-NP	NN	O	36	NMOD	O
T12	I-Entity	1186	1187	-	-	O	HYPH	O	36	NMOD	O
T12	I-Entity	1187	1194	alanine	alanine	B-NP	NN	O	36	NMOD	O
O	O	1195	1196	(	(	O	(	O	26	DEP	O
T13	B-Entity	1196	1200	fMLP	fMLP	B-NP	NN	O	26	DEP	O
O	O	1200	1201	)	)	O	)	O	23	NMOD	O
O	O	1202	1204	or	or	O	CC	O	36	NMOD	O
O	O	1205	1207	12	12	B-NP	CD	O	36	NMOD	O
O	O	1207	1208	-	-	I-NP	HYPH	O	36	NMOD	O
O	O	1208	1209	O	O	I-NP	NN	O	36	NMOD	O
O	O	1209	1210	-	-	B-NP	HYPH	O	36	NMOD	O
O	O	1210	1230	tetradecanoylphorbol	tetradecanoylphorbol	I-NP	NN	O	36	NMOD	O
O	O	1230	1231	-	-	B-NP	HYPH	O	36	NMOD	O
O	O	1231	1233	13	13	I-NP	CD	O	36	NMOD	O
O	O	1233	1234	-	-	I-NP	HYPH	O	36	NMOD	O
O	O	1234	1241	acetate	acetate	I-NP	NN	O	7	PMOD	O
O	O	1242	1243	(	(	O	(	O	39	DEP	O
O	O	1243	1246	TPA	TPA	B-NP	NN	O	39	DEP	O
O	O	1246	1247	)	)	O	)	O	36	NMOD	O
O	O	1247	1248	.	.	O	.	O	4	P	O

O	O	1249	1260	Elastatinal	Elastatinal	B-NP	NNP	O	2	SUB	O
O	O	1261	1264	had	have	B-VP	VBD	O	0	ROOT	O
O	O	1265	1269	some	some	B-NP	DT	O	2	OBJ	O
O	O	1270	1272	of	of	B-PP	IN	O	3	NMOD	O
O	O	1273	1276	the	the	B-NP	DT	O	7	NMOD	O
O	O	1277	1281	same	same	I-NP	JJ	O	7	NMOD	O
O	O	1282	1289	effects	effect	I-NP	NNS	O	4	PMOD	O
O	O	1290	1292	as	as	B-PP	IN	O	7	NMOD	O
T14	B-Entity	1293	1297	GDSP	GDSP	B-NP	NN	O	8	PMOD	O
O	O	1298	1301	but	but	O	CC	O	2	VMOD	O
O	O	1302	1305	was	be	B-VP	VBD	O	2	VMOD	O
O	O	1306	1310	less	less	B-ADJP	RBR	O	15	AMOD	O
O	O	1311	1317	potent	potent	I-ADJP	JJ	O	15	AMOD	O
O	O	1318	1321	and	and	I-ADJP	CC	O	15	AMOD	O
O	O	1322	1331	effective	effective	I-ADJP	JJ	O	11	PRD	O
O	O	1331	1332	.	.	O	.	O	2	P	O

O	O	1333	1338	These	These	B-NP	DT	O	2	NMOD	O
O	O	1339	1346	results	result	I-NP	NNS	O	3	SUB	O
O	O	1347	1358	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT	O
O	O	1359	1360	a	a	B-NP	DT	O	6	NMOD	O
O	O	1361	1371	beneficial	beneficial	I-NP	JJ	O	6	NMOD	O
O	O	1372	1378	effect	effect	I-NP	NN	O	3	OBJ	O
O	O	1379	1381	of	of	B-PP	IN	O	6	NMOD	O
T15	B-Entity	1382	1386	GDSP	GDSP	B-NP	NN	O	14	NMOD	O
O	O	1386	1387	,	,	O	,	O	14	P	O
O	O	1388	1389	a	a	B-NP	DT	O	14	NMOD	O
O	O	1390	1395	novel	novel	I-NP	JJ	O	14	NMOD	O
O	O	1396	1404	specific	specific	I-NP	JJ	O	14	NMOD	O
O	O	1405	1413	elastase	elastase	I-NP	NN	O	14	NMOD	O
O	O	1414	1423	inhibitor	inhibitor	I-NP	NN	O	7	PMOD	O
O	O	1423	1424	,	,	O	,	O	6	P	O
O	O	1425	1427	on	on	B-PP	IN	O	6	NMOD	O
O	O	1428	1431	the	the	B-NP	DT	O	18	NMOD	O
O	O	1432	1443	development	development	I-NP	NN	O	16	PMOD	O
O	O	1444	1446	of	of	B-PP	IN	O	18	NMOD	O
O	O	1447	1450	rat	rat	B-NP	NN	O	22	NMOD	O
O	O	1451	1459	cerulein	cerulein	I-NP	NN	O	22	NMOD	O
O	O	1460	1472	pancreatitis	pancreatitis	I-NP	NN	O	19	PMOD	O
O	O	1472	1473	.	.	O	.	O	3	P	O
